aTyr Pharma/$ATYR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About aTyr Pharma
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Ticker
$ATYR
Sector
Primary listing
Employees
59
Headquarters
Website
aTyr Pharma Metrics
BasicAdvanced
$58m
-
-$0.73
0.66
-
Price and volume
Market cap
$58m
Beta
0.66
52-week high
$7.29
52-week low
$0.40
Average daily volume
2.7m
Financial strength
Current ratio
5.776
Quick ratio
5.726
Long term debt to equity
17.689
Total debt to equity
20.263
Profitability
EBITDA (TTM)
-72.631
Gross margin (TTM)
-29,227.37%
Net profit margin (TTM)
-36,857.37%
Operating margin (TTM)
-38,573.68%
Management effectiveness
Return on assets (TTM)
-51.79%
Return on equity (TTM)
-105.63%
Valuation
Price to revenue (TTM)
299.091
Price to book
1.01
Price to tangible book (TTM)
1.01
Price to free cash flow (TTM)
-0.958
Free cash flow yield (TTM)
-104.39%
Free cash flow per share (TTM)
-0.618
Growth
Earnings per share change (TTM)
-8.59%
3-year revenue growth (CAGR)
-73.65%
3-year earnings per share growth (CAGR)
-19.75%
10-year earnings per share growth (CAGR)
-32.24%
What the Analysts think about aTyr Pharma
Analyst ratings (Buy, Hold, Sell) for aTyr Pharma stock.
aTyr Pharma Financial Performance
Revenues and expenses
aTyr Pharma Earnings Performance
Company profitability
aTyr Pharma News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs